Navigation Links
Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohn's Disease in the European Union
Date:3/7/2013

in moderately to severely active CD and UC patients, who had failed at least one conventional or anti-TNFα therapy.

"With a targeted mechanism of action, vedolizumab has clinical promise as a potential treatment option for people with moderate to severely active CD and UC," said Paul Rutgeerts, M.D., Ph.D., F.R.C.P., professor of medicine, Catholic University of Leuven, Belgium. "While there is no known cure, there is a need for new CD and UC treatment options, in an effort to provide patients with additional choices for managing their disease, reducing symptoms and achieving remission."

About Crohn's disease and ulcerative colitis

Crohn's disease (CD) and ulcerative colitis (UC) are the two most common forms of inflammatory bowel disease (IBD), which is marked by inflammation in the lining of the GI tract. CD can impact any part of the digestive tract, and common symptoms may include abdominal pain, diarrhea, rectal bleeding, weight loss, and/or fever. UC impacts the large intestine only, which includes the colon and the rectum. The most common symptoms of UC include abdominal discomfort and blood or pus in diarrhea. There is no known cause for CD or UC, although many researchers believe that the interaction of an outside agent, such as a virus or bacteria, with the body's immune system may trigger them. No cure exists for CD or UC; the aim of IBD treatments is to induce and maintain remission, or achieve extended periods of time when patients do not experience symptoms.

About vedolizumab

Vedolizumab was developed for the treatment of CD and UC, as a gut-selective, humanized monoclonal antibody that specifically antagonizes the alpha4beta7 (α4β7) integrin, which is expressed on a subset of circulating white blood cells. These cells have been shown to play a role in mediating the inflammatory process in CD and UC. α4β7 binds with a specific adhesion molecule primarily expressed in the intestinal tract. Ther
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Takeda and Resolve Therapeutics Enter Autoimmune Partnership
2. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
3. FDA Accepts Takeda and Lundbecks Submission of the New Drug Application for Vortioxetine for the Treatment of Major Depressive Disorder
4. Takedas Deerfield Campus Ranked Among Chicagos Top 100 Workplaces in 2012
5. Takeda Completes its Russian Pharmaceutical Manufacturing Facility
6. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
7. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
8. Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil
9. Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market Novel Antitumor Agent TAS-102
10. Bayer Submits New Drug Application for Riociguat for the Treatment of Pulmonary Arterial Hypertension and Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
11. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ), a ... today reported its financial results for the quarter ended June ... of 2014 to the same period of 2013: , ... , t:slim Pump shipments grew 64 percent to 2,235 ... ended June 30, 2014 to the same period of 2013: ...
(Date:7/31/2014)... SUNNYVALE, Calif. , July 31, 2014  Cepheid (NASDAQ: ... be speaking at the following conferences, and invited investors to ... Management Access Conference, New York, NY ... Baird Health Care Conference, New York, ... Eastern Time , Accessing Live Webcasts To access ...
(Date:7/31/2014)... --  Auxilium Pharmaceuticals , Inc. (NASDAQ: AUXL ... that the Company will release results for the second ... the opening of the U.S. financial markets. The Company ... 8:30 a.m. ET to discuss results and highlights of ... be used during the call will be available on ...
Breaking Medicine Technology:Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 3Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 4Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 5Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 6Cepheid to Webcast Upcoming Financial Presentations 2Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 2Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 3
... 22 CardioVascular,BioTherapeutics, Inc. (OTC Bulletin Board: CVBT) has ... be the sponsor and general,partner of ProDerm Limited Partnership ... up to $10 million of the clinical development for ... with CVBT,s wound healing drug, which I,believe has the ...
... Analysis of rEEG(R) Guided Medication Study Demonstrates an ... Improvement in Depression and Eating Disorder Symptoms, ... Inc.,(OTC Bulletin Board: CNSO) reported today the results ... (APA) 161st Annual Meeting by Dr.,James Greenblatt, M.D., ...
Cached Medicine Technology:Dr. Christopher Moore to Form ProDerm LP to Fund CVBT Wound Healing Trial 2Dr. Christopher Moore to Form ProDerm LP to Fund CVBT Wound Healing Trial 3CNS Response, Inc. Provides Review of Poster Session Delivered at the American Psychiatric Association 161st Annual Meeting 2CNS Response, Inc. Provides Review of Poster Session Delivered at the American Psychiatric Association 161st Annual Meeting 3CNS Response, Inc. Provides Review of Poster Session Delivered at the American Psychiatric Association 161st Annual Meeting 4CNS Response, Inc. Provides Review of Poster Session Delivered at the American Psychiatric Association 161st Annual Meeting 5CNS Response, Inc. Provides Review of Poster Session Delivered at the American Psychiatric Association 161st Annual Meeting 6
(Date:8/1/2014)... 2014 A new study published ... may contribute to the development of colorectal cancer in ... The study was authored by Alberto Martin of the ... cause intestinal cells to multiply and create tumors in ... , “What’s interesting about this study,” said Shahab ...
(Date:8/1/2014)... BellasDress has recently showcased its beautifully ... season’s gorgeous styles. The company’s lot of hot styles, ... outfits, one shoulder chiffon outfits and high low outfits. ... elegant purple prom dresses. As one of the most ... product quality. Thus, all its items are of superb ...
(Date:8/1/2014)... HealthDay Reporter THURSDAY, July 31, 2014 (HealthDay ... has a well-earned reputation as one of the world,s most ... medical care can greatly improve a person,s chances of survival. ... life-threatening havoc within the body by attacking multiple organ systems ... on the basics of "good meticulous intensive care," supporting the ...
(Date:8/1/2014)... For the first time, Textile ... & Fiber Report and the Organic Cotton Market Report ... cotton supply chain resulting in the 2013 Organic ... Director, reports, “We are looking holistically at the organic ... of a long value chain and surveying the entire ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 “When insulation ... throughout your entire home.“ In a newly released article ... Attic Insulation Needs To Be Replaced ,” Clean Crawls ... become damp, or been infested by critters. , ... quote from Clean Crawls - http://www.cleancrawl.com/contact . , ...
Breaking Medicine News(10 mins):Health News:Carbs May Contribute to Colon Cancer 2Health News:BellasDress Creates Must-have Purple Prom Dresses for Prom Attendees 2Health News:There's No Ebola Cure, But Early Intensive Treatment Boosts Survival 2Health News:There's No Ebola Cure, But Early Intensive Treatment Boosts Survival 3Health News:Surveys Reveal the Top 10 Organic Cotton Users and the Top 10 Producing Countries 2Health News:5 Signs That Insulation Should Be Replaced Detailed in a Newly Released Article By Clean Crawls 2
... TUESDAY, Jan. 25 (HealthDay News) -- There,s a worrisome uptick in ... even younger Americans, and some experts link the trend to a ... decades. That,s because the human papillomavirus (HPV) is a major ... type of sexual activity. "It seems like a pretty ...
... study, which was conducted at Sahlgrenska University Hospital in ... between the ages of 18 and 65. Half the ... and the other half to maintain their usual lifestyle. ... physiotherapist. The active group increased their physical activity on ...
... French researchers determined that infection with human immunodeficiency ... liver cancer, with more HIV infected patients dropping ... that overall survival and recurrence-free survival was not ... HIV disease. Details of this single center studythe ...
... HealthDay Reporter , MONDAY, Jan. 24 (HealthDay News) ... become the healthiest, wealthiest and most successful adults, new research ... 3 are more likely to drop out of school, break ... Researchers analyzed data on about 1,000 children born in ...
... As keyboards increasingly replace pens, new research cautions that the ... critical brain activity central to learning that is uniquely tied ... from the results of a number of experiments recently reviewed ... concluded that writing by hand is actually a very different ...
... Association of Clinical Endocrinologists (AACE) has released new medical ... Loyola physician Pauline Camacho, MD, was part of a ... public health issue. These recommendations were developed to ... quality of life for patients. They explain new treatment ...
Cached Medicine News:Health News:Rise in Some Head and Neck Cancers Tied to Oral Sex: Study 2Health News:Rise in Some Head and Neck Cancers Tied to Oral Sex: Study 3Health News:Rise in Some Head and Neck Cancers Tied to Oral Sex: Study 4Health News:Patients infected with HIV have higher drop-out rate for liver transplantation 2Health News:Self-Control Could Turn Kids Into Successful Adults 2Health News:Self-Control Could Turn Kids Into Successful Adults 3Health News:Pen Mightier Than Keyboard for Making Imprint on Brain 2Health News:Loyola physician helps develop national guidelines for osteoporosis 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: